Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1039028

	registered interest
	date	10/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Asparaginase
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether Erwinase will be available for the treatment for children with acute lymphoblastic leukaemia between January 2019 and March 2019; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	207238
	answer	answer is ministerial correction date of answer 18/01/2019 answer text <p>Erwinase is produced by Porton Biopharma Ltd (PBL) and is licensed and distributed by Jazz Pharmaceuticals under a global licencing agreement.</p><p> </p><p>Due to increased demand for Erwinase and because PBL are manufacturing at capacity, until increases in capacity are brought into beneficial use there will be occasional stock-outs.</p><p> </p><p>The product is currently in stock in the United Kingdom. The Department has been informed, it is likely there will be a short stock-out in early February 2019 and then a further batch is planned to be released to Jazz Pharmaceuticals, who are responsible for the packaging/distribution and allocation of worldwide product supply, anticipated to reach the UK market by mid-February 2019 which should last until the end of March 2019.</p><p> </p><p>The Department and Public Health England (PHE) are in close contact with, and have been kept informed by the PBL management of short periods of interrupted supply. PBL have and will be implementing a series of initiatives to increase capacity and better supply the market in both the short and long term. PBL are fully aware of the consequences that the unavailability of Erwinase has on patients and are absolutely committed to working with all involved to resolve any issues and be able to supply this critical medicine.</p><p> </p><p>The Department and PHE will continue to monitor the situation closely.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/01/2019 12:18:00 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1017502

	registered interest
	date	30/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what proportion of (a) leukaemia, (b) non-Hodgkin lymphoma, (c) Hodgkin lymphoma and (d) myeloma cases were diagnosed at each cancer stage in each of the last five years.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	197620
	answer	answer is ministerial correction date of answer 10/12/2018 answer text <p>This information is not held centrally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 10/12/2018 15:38:39 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

1002558

	registered interest
	date	06/11/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the ability of the NHS long-term plan to (a) tackle the evolving challenges of cancer and (b) ensure that people are able to access personalised and tailored support after they have finished cancer treatment itself.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	188796
	answer	answer is ministerial correction date of answer 14/11/2018 answer text <p>The NHS Long Term Plan provides an excellent opportunity to look at how cancer and other services can be further improved over the next decade. The plan is currently in development and will be published later in the year.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 14/11/2018 11:29:49 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

987817

	registered interest
	date	15/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the initiatives announced by the Prime Minister on 3 October 2018 on early detection rates for cancer include blood cancer; and if he will make a statement.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	179183
	answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>NHS England is completely clear that the new 75% early diagnosis ambition announced by the Prime Minister covers all cancers, and not just the 10 currently included in the Public Health Outcomes Framework (PHOF) early diagnosis metric. NHS England is keen to work with the voluntary sector organisations and charities representing some of the other cancers not currently included in the PHOF metric on how we best measure progress towards the ambition moving forwards.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:57:18 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith

994628

	registered interest
	date	25/10/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Haematological Cancer: Medical Treatments
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the NHS England news releases of 5 September and 5 October, when he plans to make CAR-T cell therapy available to (a) people aged under 25 with acute lymphoblastic leukaemia and (b) adult patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after two or more previous therapies have failed.
	tabling member constituency	Crawley
	tabling member printed	Henry Smith
	uin	183918
	answer	answer is ministerial correction date of answer 02/11/2018 answer text <p>NHS England is working with the manufacturers and National Health Service providers to prepare the NHS to begin delivering Chimeric Antigen Receptor T Cell (CAR-T) therapy - the first in a wave of treatments in a new era of personalised medicine and part of the NHS’s long-term plan to upgrade cancer service. The first treatment that will be available to patient is tisagenlecleucel (Kymriah) as an option for treating children and young people up to 25 years old with B cell acute lymphoblastic leukaemia that is refractory, in relapsed post-transplant or in second or later relapse.</p><p> </p><p>NHS England anticipates that the National Institute for Health and Care Excellence will recommend this treatment for entry into the Cancer Drugs Fund in mid-November. If so, funding will be made immediately available, following a successful commercial deal with the manufacturer Novartis. We anticipate the first patients will begin their treatment in late November 2018. The phased implementation required by the manufacturer and the NHS means that full capacity to treat eligible patients will take some months to achieve and a National CAR-T Clinical Panel will convene in mid-November to assure equity of access and prioritise eligible patients.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 02/11/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
	tabling member	3960 label Biography information for Henry Smith